Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAS1 | P04201 | 1/20 | 0.46 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.39 |
| ▸ | EDNRA | P25101 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183402 | 0.90 | MAS1 (0.54) | MAS1GP6AGTR2AGTR1 | |
| SCHEMBL7382680 | 0.87 | MAS1 (0.47) | MAS1AGTR2EDNRAAGTR1 | |
| SCHEMBL3975298 | 0.84 | AGTR2 (0.48) | MAS1AGTR2AGTR1 | |
| SCHEMBL6183698 | 0.81 | MAS1 (0.45) | MAS1AGTR2 | |
| SCHEMBL4106849 | 0.79 | MAS1 (0.60) | MAS1AGTR2EDNRAAGTR1 | |
| SCHEMBL4106426 | 0.78 | MAS1 (0.59) | MAS1AGTR2EDNRAAGTR1 | |
| SCHEMBL7383678 | 0.78 | MAS1 (0.55) | MAS1AGTR2AGTR1 | |
| SCHEMBL24637548 | 0.76 | AGTR2 (0.61) | MAS1AGTR2AGTR1 | |
| SCHEMBL3902365 | 0.76 | MAS1 (0.55) | MAS1AGTR2AGTR1 | |
| SCHEMBL3903957 | 0.76 | MAS1 (0.56) | MAS1AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185527-B1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA GMBH (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-06-20 | — | — | US | disclosed |
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-08-30 | — | — | US | disclosed |
| US-6235766-B1 | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AGTR1, NPR1, EDNRB | MAS1 362/4885GP6 433/4885AGTR2 7/4885 |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AGTR1, NPR1, EDNRB | MAS1 427/4885GP6 300/4885AGTR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.